AntiCancer Inc.
http://www.anticancer.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AntiCancer Inc.
US court invalidates one of two Gemzar patents
A US district court has granted a motion filed by Sun Pharma for partial summary judgement in its three-year battle over Lilly's Gemzar (gemcitabine HCl for injection) – invalidating Lilly's method-of-use patent (the '826 patent), which includes paediatric exclusivity and is set to expire in May 2013.
Indian court rejects patent linkage in Bayer's sorafenib case - update
The Delhi High Court has indicted Bayer for attempting to use "speculative" litigation in India, in a case concerning Cipla's application to introduce a generic version of Bayer's anticancer Nexavar (sorafenib tosylate).
Indian court rejects patent linkage in Bayer'ssorafenib case
The High Court in Delhi, India has indicted Bayer for "speculative" litigation in a case concerning Cipla's marketing application for a generic version of the anticancer sorafenib tosylate.
Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), met one of its co-primary endpoints, progression-free survival (PFS), but not the other, overall survival, in patients with KRAS wild-type metastatic colorectal cancer (mCRC) in the pivotal Phase III "181" trial testing it as second-line therapy.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice